Skip to main content

Home-Based Ovulation Monitoring Feasible for Timing Frozen-Thawed Embryo Transfer

Medically reviewed by Drugs.com.

By Lori Solomon HealthDay Reporter

THURSDAY, Sept. 14, 2023 -- Home-based monitoring of ovulation is noninferior to hospital-controlled monitoring to time frozen-thawed embryo transfer (FET) for pregnancy, according to a study published online Sept. 4 in The Lancet.

Tjitske Zaat, M.D., from the University of Amsterdam, and colleagues compared ongoing pregnancy rates after home-based monitoring versus hospital-controlled monitoring with ovulation triggering. The analysis included 1,464 women (aged 18 to 44 years) with a regular ovulatory menstrual cycle who were randomly assigned (1:1) to home-based monitoring or hospital-controlled monitoring.

The researchers found that ongoing pregnancy occurred in 20.8 percent of individuals in the home-based monitoring group and in 20.9 percent in the hospital-controlled monitoring group (risk ratio [RR], 0.99; 90 percent confidence interval [CI], 0.81 to 1.22; risk difference [RD], –0.14; 90 percent CI, –3.63 to 3.36). Predetermined noninferiority was achieved (RR, 1.00; 90 percent CI, 0.81 to 1.23; RD, –0.08; 90 percent CI, –3.60 to 3.44).

"Monitoring ovulation at home means a hospital visit once for the placement of these embryos instead of three to four times for hospital monitoring," Zaat said in a statement. "This is more sustainable and reduces the cost of treatment by up to 80 percent."

Several authors disclosed ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted September 2023

Read this next

AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours

WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...

Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million

TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...

Patient–Primary Care Provider Language Concordance Tied to Better Outcomes

TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.